Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.
Try Elite for Free
Login Sign up free
Home Screener Maps Charts News Groups Insider Futures Forex Crypto Portfolio Calendar
Pricing
Market News Market Pulse Stocks News ETF News Crypto News

Cabaletta Bio

Contributing Author

Recent Articles by Cabaletta Bio

Sep-01
Cabaletta Bio to Participate in Upcoming Investor Conferences CABA +6.11% GlobeNewswire
Aug-13
Cabaletta Bio Reports Second Quarter 2026 Financial Results and Provides Business Update CABA GlobeNewswire
Jun-03
Cabaletta Bio Announces New Rese-cel Data and Development Updates Across Autoimmune Portfolio, Including Encouraging Early PC-Free Lupus Findings, at EULAR 2026 Congress CABA GlobeNewswire
May-14
Cabaletta Bio Reports First Quarter 2026 Financial Results and Provides Business Update CABA GlobeNewswire
May-14
Cabaletta Bio Presents Preconditioning-free Clinical Data and Automated Manufacturing Translational Data for Rese-cel at ASGCT 2026 Annual Meeting CABA GlobeNewswire
May-04
Cabaletta Bio Announces Pricing of $150 Million Underwritten Offering CABA +30.27% GlobeNewswire
Apr-28
Cabaletta Bio and Cellares Announce 10-Year Commercial Supply Agreement for Rese-cel CABA GlobeNewswire
Apr-27
Cabaletta Bio Announces Multiple Upcoming Presentations, Including Data on Rese-cel without Preconditioning and Rese-cel with Automated Manufacturing, at the ASGCT 2026 Annual Meeting CABA GlobeNewswire
Mar-23
Cabaletta Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update CABA GlobeNewswire
Feb-24
Cabaletta Bio to Participate in the TD Cowen 46th Annual Health Care Conference CABA +13.45% GlobeNewswire
Feb-05
Cabaletta Bio to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 CABA -7.17% GlobeNewswire
Jan-12
Cabaletta Bio Announces 2026 Strategic Priorities CABA +5.24% GlobeNewswire
Nov-10
Cabaletta Bio Reports Third Quarter 2025 Financial Results and Provides Business Update CABA GlobeNewswire
Nov-04
Cabaletta Bio to Participate in Upcoming Investor Conferences in November and December CABA -10.30% GlobeNewswire
Oct-27
Cabaletta Bio Presents Positive Clinical Data and Development Updates for Rese-cel at ACR Convergence 2025 CABA +12.96% GlobeNewswire
Oct-14
Cabaletta Bio Announces Appointment of Steve Gavel as Chief Commercial Officer and Award of Inducement Grant CABA +16.06% GlobeNewswire
Oct-09
Cabaletta Bio Presents First Rese-cel Data with No Preconditioning Demonstrating Biologic Activity and Early Clinical Responses at the 2025 ESGCT Annual Congress CABA +18.26% CABA -18.60% GlobeNewswire
Aug-27
Cabaletta Bio to Participate in Upcoming Investor Conferences in September CABA GlobeNewswire
Aug-07
Cabaletta Bio Reports Second Quarter 2025 Financial Results and Provides Business Update CABA GlobeNewswire
Jun-11
Cabaletta Bio Announces Pricing of Public Offering of Securities CABA -25.53% GlobeNewswire
Jun-11
Cabaletta Bio Announces Proposed Public Offering of Securities CABA -25.53% GlobeNewswire
Jun-11
Cabaletta Bio Announces New Rese-cel Safety and Efficacy Data in Patients with Myositis, Lupus and Scleroderma to Be Presented at the EULAR 2025 Congress CABA -25.53% GlobeNewswire
May-29
Cabaletta Bio to Participate in the Jefferies Global Healthcare Conference CABA GlobeNewswire
May-15
Cabaletta Bio Announces 2027 Rese-cel BLA Submission Anticipated in Myositis Following Recent FDA Alignment on Registrational Cohorts CABA +39.23% GlobeNewswire
Affiliate • Advertise • API and Exports • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information
Stock quotes delayed by 1 minute. Futures and options delayed by 15 minutes.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)